Ionis and Biogen's muscular disorder treatment meets main goal

Nov 7 (Reuters) - Biogen Inc and Ionis

Pharmaceuticals said their investigational treatment

for a type of rare genetic muscular disorder met its main goal

in an interim analysis of a late-stage study.

Read more